Cipla shares broke out above ₹1,580–₹1,590 on strong volumes, with technical indicators signaling further gains.

Pharma companies are separating consumer healthcare businesses to drive growth, facing challenges in a competitive market.

If the deal works out, it would be the largest in the Indian pharma sector, analysts said. Cipla's shares jumped as much as 4.1% after the results and were up 1.9%, as of 3:20 p.m. IST.

Nomura’s June 2025 analysis shows Indian pharma majors like Sun Pharma, Dr. Reddy’s, Cipla, Lupin, and Zydus posting strong ...

Cipla's share price experiences a slight decline with a 1.13% drop in weekly returns, despite surpassing its 20-day Simple Moving Average.

The Nifty Pharma Index gained more than 1% amid a weak Indian stock market on a day when the benchmark Nifty 50 Index dipped ...

India's Torrent Pharmaceuticals is in talks with private equity funds CVC Capital Partners and Bain Capital to raise up to $1.5 billion to bid for India's Cipla, according to three sources with ...

Zee Business analysts Ansh Jogendra Bhilwar and Pooja Tripathi have shared a number of calls for trading and investing today, ...

Dr Reddy's Laboratories (DRL), Cipla, Sun Pharma, and Mankind Pharma, among others, are laying the groundwork for Day 1 ...

The market may continue to consolidate with a negative bias in the upcoming sessions. Below are some short-term trading ideas to consider.

Cipla's shares closed 2.03% higher on Friday after the results. They have risen nearly 17% in the September quarter, outpacing a 12% rise in the Nifty Pharma index (.NIPHARM).